Aprea Therapeutics’ (APRE) Buy Rating Reaffirmed at HC Wainwright

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $20.00 price target on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a report on Tuesday, May 14th.

Aprea Therapeutics Stock Down 4.2 %

Shares of NASDAQ:APRE traded down $0.14 during trading on Monday, hitting $3.22. The stock had a trading volume of 19,911 shares, compared to its average volume of 19,966. Aprea Therapeutics has a 12 month low of $3.20 and a 12 month high of $8.85. The firm’s fifty day moving average is $4.01 and its 200 day moving average is $5.29. The company has a market capitalization of $17.48 million, a PE ratio of -0.97 and a beta of 1.04.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Tuesday, May 14th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.11. The business had revenue of $0.38 million for the quarter. Aprea Therapeutics had a negative return on equity of 56.78% and a negative net margin of 1,317.82%. Equities research analysts expect that Aprea Therapeutics will post -2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.